Sevelamer hydrochloride is an orally active and phosphate binding agent used for research of hyperphosphatemia with chronic kidney disease. Sevelamer hydrochloride consists of polyallylamine that is crosslinked with epichlorohydrin[2].In Vitro:Sevelamer hydrochloride (15 mg/mL; pH=6 or 8) decreases serum levels of gut-derived uremic toxins (such as IAA) or limits the elevation of gut-derived uremic toxins (initial concentration=1 μg/mL or 10 μg/mL)[2].
In Vivo:Sevelamer hydrochloride (1% mixed in diet; p.o.; once daily for 5 weeks) reduces Npt2b-deficient mice serum phosphate levels, but fails to reduce the level in uremic WT mice.Sevelamer hydrochloride leads to a significant decrease in osteoclast number in uremic WT mice with a trend toward further decrease in Npt2b-/- mice.Sevelamer hydrochloride leads to a significant increase in Npt2b protein expression.